<DOC>
	<DOCNO>NCT00109837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) , give drug different combination may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>S0333 Combination Chemotherapy Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine probability 1-year continuous complete remission patient newly diagnose acute lymphoblastic leukemia treat first induction chemotherapy comprise daunorubicin , vincristine , prednisone , pegaspargase ; second induction chemotherapy comprise high-dose cytarabine mitoxantrone . Secondary - Determine frequency severity toxic effect induction regimens follow consolidation therapy comprise cyclophosphamide , cytarabine , mercaptopurine , methotrexate maintenance chemotherapy comprise mercaptopurine , methotrexate , vincristine , doxorubicin , dexamethasone , cyclophosphamide , thioguanine , cytarabine patient . Other objective ( fund allows ) : - To evaluate preliminary manner significance detect minimal residual disease prognostic factor survival relapse-free survival patient receive chemotherapy - To evaluate preliminary manner pattern gene expression patient enter onto trial relationship cytogenetics/FISH risk classification , overall survival , relapse-free survival OUTLINE : This multicenter study . - First induction chemotherapy : Patients receive daunorubicin IV day 1-3 ; vincristine IV day 1 , 8 , 15 , 22 ; prednisone IV orally day 1-28 , follow taper day 35 ; pegaspargase IV subcutaneously ( SC ) day 15 . Patients CNS leukemia also receive methotrexate intrathecally ( IT ) intraventricularly twice weekly oral leucovorin calcium four time daily 4 dos administration methotrexate . When blast longer present spinal fluid , patient receive methotrexate IT intraventricularly weekly 4 week monthly 1 year . Patients reevaluate day 28 . Patients achieve A1 bone marrow status B1 peripheral blood status resistant disease proceed second induction therapy . - Second induction chemotherapy : Patients receive high-dose cytarabine IV day 1-5 ; mitoxantrone IV day 3 ; filgrastim ( G-CSF ) SC IV begin day 7 continue blood count recover . Patients CNS leukemia also receive methotrexate leucovorin calcium first induction chemotherapy . Patients reevaluate day 28 . Patients achieve A1 bone marrow status B1 peripheral blood status extramedullary disease ( CNS involvement ) proceed consolidation chemotherapy . Patients resistant disease OR Philadelphia chromosome- BCR/ABL-positive disease remove study receive double induction chemotherapy . - Consolidation chemotherapy : Patients receive cyclophosphamide IV day 1 , 15 , 29 ; cytarabine IV day 2-5 16-19 ; oral mercaptopurine day 1-28 ; methotrexate IT intraventricularly day 2 , 9 , 16 , 23 . Patients CNS leukemia also undergo cranial radiotherapy daily , 5 day week , 2 week . Patients complete remission proceed maintenance chemotherapy . - Maintenance chemotherapy : - Course 1 : Patients receive oral mercaptopurine day 1-63 oral methotrexate day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . Patients proceed course 2 blood count recover . - Course 2 : Patients receive vincristine IV doxorubicin IV day 1 , 8 , 15 , 22 oral dexamethasone day 1-28 . Patients proceed course 3 blood count recover . - Course 3 : Patients receive cyclophosphamide IV day 1 ; oral thioguanine day 1-14 ; cytarabine IV day 3-6 10-13 . Patients proceed course 4 blood count recover . - Course 4 : Patients receive oral mercaptopurine daily 2 year oral methotrexate weekly 2 year . Treatment continue absence disease relapse unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year , every 6 month 1 year , annually 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute lymphoblastic leukemia ( ALL ) , meet follow criterion : FAB class L1 L2 disease Mixed lineage ALL Phnegative/BCR/ABLnegative Newly diagnose disease Patients follow diagnosis eligible : FAB class L3 ALL NonHodgkin 's lymphoma Chronic myelogenous leukemia lymphoid blast crisis Mixed lineage acute myeloid leukemia Acute minimally differentiate myeloid leukemia ( M0 ) Must register protocol SWOG9007 AND SWOGS9910 PATIENT CHARACTERISTICS : Age 18 64 Performance status Zubrod 03 Life expectancy Not specify Hematopoietic Not specify Hepatic No chronic liver disease Hepatitis panel , include hepatitis B C , negative History hepatitis A positive antibody allow Renal Creatinine ≤ 1.5 time upper limit normal OR Creatinine clearance &gt; 60 mL/min Cardiovascular Left ventricular function normal Ejection fraction ≥ 50 % MUGA 2dimensional echocardiogram No symptomatic congestive heart failure No coronary artery disease No cardiomyopathy No uncontrolled arrhythmia Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior remission induction chemotherapy ALL Prior hydroxyurea control WBC count allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior treatment ALL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>